Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2011 Dec 20;287(8):6002–6013. doi: 10.1074/jbc.M111.310110

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2012 by The American Society for Biochemistry and Molecular Biology, Inc.

PMC Copyright notice

FIGURE 5. — Effect of intrathecal treatment with Cavβ₃-specific siRNA (5 μg per day for 3 days) on the expression level of Cavβ₃ in the DRG and spinal cord of SNL rats. A, effect of Cavβ₃-specific siRNA on the mRNA level of Cavβ₃ and Cavβ₄ in the DRG of SNL rats (n = 4 in each group). B, effect of Cavβ₃-specific siRNA on the mRNA level of Cavβ₃ and Cavβ₄ in the dorsal spinal cord of SNL rats (n = 4 in each group). C, Western blots (left) and quantification (right, n = 4 in each group) of the protein amount of the Cavβ₃ subunit in the DRG ipsilateral and contralateral to SNL in rats treated with Cavβ₃-specific siRNA or control siRNA. D, Western blots (left) and quantification (right, n = 4 in each group) of the protein amount of the Cavβ₃ subunit in the dorsal spinal cord ipsilateral and contralateral to SNL in rats treated with Cavβ₃-specific siRNA or control siRNA. Ipsi, ipsilateral (nerve injury) side; Cont, contralateral (control) side. *, p < 0.05, compared with the corresponding value in control siRNA-treated group.